# KPV: Research Overview — Lazarus Research Peptides > A literature summary of KPV (Lys-Pro-Val), the anti-inflammatory C-terminal tripeptide of alpha-MSH: PepT1 uptake, NF-kB and MAP-kinase suppression, murine colitis models, and the entirely preclinical evidence base. Three amino acids from alpha-MSH — the anti-inflammatory piece, without the tanning. Studied chiefly in models of gut inflammation, with no human trials yet. ## The short version KPV is a tripeptide — lysine, proline, valine — corresponding to residues 11 through 13 of the hormone alpha-melanocyte-stimulating hormone (alpha-MSH). That three-amino-acid tail retains the parent hormone's anti-inflammatory activity while dropping the melanogenic (pigment-producing) effect entirely [17]. Unlike the thymic peptides on this desk, KPV does not directly orchestrate immune-cell development. It works downstream, quieting the inflammatory signaling that drives tissue damage. Most of its research is in mouse models of gut inflammation, where it reduces colonic injury and accelerates mucosal healing [15][16]. Be clear-eyed: there are no published human clinical trials of KPV. It is sold for laboratory research only, not an approved drug or supplement, and this page recommends no dose. ## What it is KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val). Its molecular formula is C16H30N4O4. The name derives from its amino-acid sequence: **K** (lysine), **P** (proline), **V** (valine). It corresponds to residues 11-13 — the C-terminal sequence — of alpha-MSH, which is why it is also written as alpha-MSH(11-13). Its defining feature in the literature is anti-inflammatory activity *without* the pigmentary (melanogenic) action of the full hormone [17]. It is not a melanocortin agonist for tanning purposes. It is a research peptide with no approved drug or dietary-supplement status in any major jurisdiction and no validated human pharmacokinetics. ## How it works KPV dampens inflammation by suppressing two master inflammatory signaling nodes inside cells: the transcription factor *NF-kB* and the *MAP-kinase* pathways. Quieting these reduces the output of pro-inflammatory cytokines including IL-1beta and TNF-alpha [15]. There is a particularly neat feature in the gut. KPV is small enough to be transported directly into intestinal epithelial cells by the di/tripeptide transporter *PepT1* (gene SLC15A1), and PepT1 is upregulated precisely in inflamed intestinal tissue — so the uptake route becomes most active at sites of active inflammation [15]. At nanomolar concentrations taken up via PepT1, KPV inhibited NF-kB and MAP-kinase activation and lowered pro-inflammatory cytokine secretion in both epithelial and immune cells [15]. Critically, its anti-inflammatory effect was retained in MC1R-deficient mice, confirming an MC1R-independent mechanism — it is not simply acting through the classic melanocortin receptor [16]. ## What the research shows *Mechanism in cells and mice.* The foundational study demonstrated PepT1-mediated KPV uptake into human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells; nanomolar KPV inhibited NF-kB and MAP-kinase activation and reduced pro-inflammatory cytokine secretion; oral KPV reduced the severity of DSS- and TNBS-induced colitis in C57BL/6 mice [15]. *Colitis recovery.* In murine colitis (DSS model and CD45RBhi adoptive-transfer model), KPV produced earlier recovery, stronger regain of body weight, reduced colonic inflammatory infiltrate and lower myeloperoxidase activity; the effect persisted in MC1R-deficient mice, establishing an MC1R-independent route [16]. *Targeted oral delivery.* Because free KPV is peptidase-labile, much recent work is formulation science. Orally administered hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered KPV to inflamed colon tissue and reduced colitis severity more effectively than non-targeted formulations, downregulating TNF-alpha and accelerating mucosal healing [14]. *Combination nanodrug.* A 2024 PepT1-targeted nanodrug co-assembling KPV with an immunosuppressant improved both acute and chronic DSS-induced colitis in mice, restoring tight-junction proteins and reducing inflammatory cytokines beyond either agent alone [13]. *Breadth review.* A comprehensive review of alpha-MSH and related tripeptides describes KPV and relatives showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic and organ-injury models; KPV is delineated as the anti-inflammatory option without pigmentary action [17]. ## Where it fits, cautions & safety No community-anecdote reports are compiled in this desk's source material for KPV; the cautions below are drawn from the cited literature. - *No human trials.* The entire efficacy literature is in vitro and animal (chiefly murine colitis); human dosing, efficacy and safety are unestablished [15]. - *Peptidase fragility.* Free KPV is a small, labile tripeptide with no validated human pharmacokinetics; much of the field's recent effort is formulation work to keep it intact long enough to act [14]. - *Marketing outruns evidence.* Promotion of KPV for gut health, skin, or general anti-inflammatory use runs ahead of a literature that is mechanistic and preclinical, not clinical. - *Not a tanning peptide.* Although KPV derives from alpha-MSH, it should be distinguished from melanocortin agonists used for pigmentation; its defining property is anti-inflammatory action *without* pigment effect [17]. - *Research-use status.* KPV is a research chemical for laboratory use only; it is not an approved drug or dietary supplement. ## Where it fits in immune research KPV is the anti-inflammatory edge of this desk. Where [Thymosin Alpha-1](/thymosin-alpha-1) and [Thymulin](/thymulin) operate at the level of T-cell development and thymic output, KPV works downstream — quieting the NF-kB and MAP-kinase inflammatory noise that can sustain tissue damage [15]. Its evidence is the most uniformly preclinical of the three (no human trials at all), but its mechanism is precisely mapped, including the PepT1 transporter specificity and MC1R-independence. It completes the desk's immune picture from systemic maturation down to local mucosal control. See the [comparison page](/compare). ![KPV research illustration](/images/kpv.webp) --- A literature digest of peer-reviewed immune and thymic peptide research — citations in hand, no products on offer.